FDA Clearing Backlog Of Post-Marketing Studies, But Progress May Slow
This article was originally published in The Pink Sheet Daily
Executive Summary
While more than half of the post-marketing commitment backlog from 2007 and earlier has been cleared from FDA’s books, but the portion of “delayed” studies has remained consistent.
You may also be interested in...
Scrutiny Urged For FDA Divisions With High Number Of Delayed Postmarketing Studies
Postmarketing studies are more likely to be delayed in some Center for Drug Evaluation and Research review divisions than others, and one of FDA’s consultants wants the agency to find out why.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.